MacroGenics, Inc. is a biopharmaceutical company focused on discovering and developing antibody-based therapeutics for the treatment of cancer, as well as various autoimmune disorders and infectious diseases. The Company develops new therapeutic product candidates using its antibody-based technology platforms and also in partnership with other biopharmaceutical companies. MacroGenics has a pipeline of product candidates in human clinical testing, primarily against various cancers. These include two product candidates developed using Fc Optimization platform, namely margetuximab, an antibody for the treatment of certain types of metastatic breast cancers and gastroesophageal cancers, and MGA271, an antibody to impact various tumors through multiple potential mechanisms of action. In addition, the Company has created different product candidates based on Dual-Affinity Re-Targetingr (DART) platform.

TypePublic
HQRockville, US
Founded2000
Size (employees)318 (est)
Websitemacrogenics.com
MacroGenics was founded in 2000 and is headquartered in Rockville, US
Report incorrect company information

Viewing summary data as a guest

Sign up for free to see all data

Key People/Management at MacroGenics

Scott Koenig

Scott Koenig

President & Chief Executive Officer and Board Member
Ezio Bonvini

Ezio Bonvini

Senior Vice President, Research
Eric Risser

Eric Risser

Vice President, Development
James Karrels

James Karrels

Vice President, Chief Financial Officer
Lynn Cilinski

Lynn Cilinski

Vice President, Controller and Treasurer
Show more

MacroGenics Office Locations

MacroGenics has offices in Rockville and South San Francisco
Rockville, US (HQ)
9640 Medical Center Dr
Rockville, US
15235 Shady Grove Rd
South San Francisco, US
1 Corporate Dr
Show all (3)
Report incorrect company information

MacroGenics Financials and Metrics

MacroGenics Revenue

MacroGenics's revenue was reported to be $157.74 m in FY, 2017
USD

Revenue (Q2, 2018)

23.5 m

Net income (Q2, 2018)

(92.8 m)

EBIT (Q2, 2018)

(94.5 m)

Market capitalization (20-Sep-2018)

958.4 m

Closing stock price (20-Sep-2018)

22.7

Cash (30-Jun-2018)

238.7 m
MacroGenics's current market capitalization is $958.4 m.
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Revenue

58 m47.8 m100.9 m91.9 m157.7 m

Revenue growth, %

(18%)111%(9%)

General and administrative expense

29.8 m32.7 m

R&D expense

122.1 m147.2 m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q1, 2018Q2, 2018

Revenue

20.2 m14.7 m9.2 m18.4 m71.3 m6.7 m14.7 m2.8 m80.7 m3.3 m2.1 m1.7 m4.7 m23.5 m

General and administrative expense

2 m3.3 m4.1 m3.7 m4.7 m5.3 m6 m6.1 m7.2 m7.2 m7.5 m8.4 m9.2 m20.4 m

R&D expense

11.1 m14.6 m17.3 m18.6 m21.5 m22.7 m24.1 m27.3 m33.3 m30.3 m32.8 m34.5 m45.7 m97.7 m

Operating expense total

13.1 m17.8 m21.5 m22.3 m26.1 m28 m30.1 m33.5 m40.6 m37.5 m40.3 m42.8 m54.9 m118.1 m
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Cash

116.5 m157.6 m196.2 m84.1 m211.7 m

Accounts Receivable

2 m2.9 m1.2 m2.8 m13.6 m

Inventories

Current Assets

119.5 m164.7 m342.4 m283.9 m322.3 m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q1, 2018Q2, 2018

Cash

33.6 m198.7 m194 m179.2 m263.1 m235 m365.8 m152 m62.3 m109.9 m40.5 m116.6 m200.4 m238.7 m

Accounts Receivable

2.3 m1.7 m2.6 m5.3 m1.7 m4.3 m2.7 m2.5 m78.4 m3 m2.1 m2 m7.3 m17.8 m

Current Assets

37 m202.4 m198.8 m187 m268.5 m242.4 m370.5 m309.3 m348.4 m316.3 m251 m250.1 m271 m322.1 m

PP&E

4.5 m5.1 m5.4 m5.6 m7.2 m9.4 m11.5 m14.3 m18.3 m18.5 m17.4 m23.2 m53.4 m57.5 m
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Net Income

(260.8 k)(38.3 m)(20.1 m)(58.5 m)(19.6 m)

Depreciation and Amortization

1.2 m1.8 m2.9 m7.6 m7.2 m

Inventories

Accounts Payable

(570.1 k)(1.5 m)(163 k)2.2 m(1.5 m)
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q1, 2018Q2, 2018

Net Income

2.9 m(3.1 m)(15.4 m)(19.3 m)(30.4 m)10.1 m(23.7 m)(37.7 m)(78.3 m)(49.5 m)(92.8 m)

Depreciation and Amortization

834.6 k398.2 k835 k1.3 m546 k1.2 m1.7 m1.8 m3.6 m5.6 m2 m4 m1.3 m2.5 m

Accounts Payable

(1.9 m)2 m808 k1.2 m(225 k)184 k872 k(388 k)(355 k)(133 k)(2.2 m)(2 m)7.8 m(684 k)

Cash From Operating Activities

(13 m)5.9 m1.7 m(12.6 m)43.6 m18.1 m10.5 m(31.9 m)(65.1 m)(15.4 m)(35.3 m)(66.1 m)(31.3 m)(89 m)
USDY, 2018

Financial Leverage

1.2 x
Show all financial metrics
Report incorrect company information

MacroGenics News and Updates

MacroGenics Announces Participation in Three Upcoming Investor Conferences

Rockville, MD, Aug. 30, 2018 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company's management will par…

MacroGenics to Present at Wedbush PacGrow Healthcare Conference

ROCKVILLE, MD, Aug. 09, 2018 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company's management will pro…

MacroGenics Provides Update on Corporate Progress and 2nd Quarter 2018 Financial Results

ROCKVILLE, Md., Aug. 07, 2018 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today provided an update on its corporate progress and…
Report incorrect company information

MacroGenics Company Life and Culture

Report incorrect company information